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The treatment of neurodegenerative and psychiatric disorders remains a challenge in medical research. 2 
Several strategies have been developed over the years, either to overcome the blood-brain barrier or to 3 
achieve a safer or faster brain delivery, one of them being intranasal (IN) administration. The possibility of 4 
direct nose-to-brain transport offers enhanced targeting and reduced systemic side effects. Nevertheless, 5 
labile, low soluble, low permeant and/or less potent drugs might need a formulation other than the common 6 
solutions or suspensions. For that, the formulation of nanosystems is considered a promising approach, since 7 
it can protect drugs from chemical and/or metabolic degradation, enhance their solubility, or offer transport 8 
through biological membranes. However, the understanding of the factors promoting efficient brain targeting 9 
when using nanosystems through the nasal route is currently patchy and incomplete.  10 
The main purpose of the present review was to evaluate the association between brain delivery efficacy (in 11 
terms of brain targeting, brain bioavailability and time to reach the brain) and nanosystem type. For that, we 12 
performed a systematic bibliographic search and analysis. Furthermore, study designs, nanosystem 13 
properties, and reporting quality were also analyzed and discussed. 14 
It was found a high heterogeneity in of how pre-clinical brain targeting studies have been conducted, 15 
analyzed and reported in scientific literature, which surely originates a significant degree of bias and data 16 
dispersion. This review attempts to provide some systematization recommendations, which may be useful for 17 
researchers entering the field, and assist in increasing the uniformity of future reports.  18 
The analysis of literature data confirmed that there is evidence of the advantage of the IN route (when 19 
compared to the intravenous route) and in using carrier nanosystems (when compared to IN solutions) for 20 
brain delivery of a large set of drugs. Among the most represented nanosystem classes, microemulsions had 21 
some of the lowest values in pharmacokinetic ratios, while polymeric micelles had some of the best. 22 
Nevertheless, brain targeting efficacy comparisons between nanosystem groups had little statistical 23 
significance, and the superiority of the polymeric micelles group disappeared when nanosystems were 24 
compared to the respective IN drug solutions. Some drugs reached the brain so efficiently, even as drug 25 
solutions, that further benefit from formulating them in nanosystems became less evident.  26 
 27 
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ATCC - anatomical therapeutic chemical classification; AUC - area under the curve; BBB - blood-brain 23 
barrier; B%brain IN/IV – comparative brain bioavailability (IN vs IV); DTE% - drug targeting efficiency; DTP% 24 
- direct transport percentage; IN - intranasal; IV - intravenous;  NLC - nanostructured lipid carriers; PDI - 25 
polydispersity index; PK - pharmacokinetic; PM - polymeric micelles; PN - polymeric nanoparticles; 26 
RB%brain - relative brain bioavailability; RDTE% - relative drug targeting efficiency; RDTP% - relative direct 27 
transport percentage; rS - Spearman’s correlation coefficient; rxy - Pearson’s correlation coefficient; SEM - 28 
standard error of the mean; SLN - solid lipid nanoparticles; Tmax - time required to reach maximum 29 
concentration  30 
 
5 
1. Introduction 1 
Neurodegenerative and psychiatric disorders have always been an important focus of medical research due to 2 
their high incidence and severe consequences, including disability and death. For example, Alzheimer’s 3 
disease and other dementias were among the top 10 causes of death in 2015, with 1.57 million deaths 4 
globally, and schizophrenia has been estimated to affect approximately 1% of the general population 5 
worldwide [1,2]. Given the chronicity and rapid deterioration induced by neurodegenerative diseases, and the 6 
ongoing aging of the western world population, the attention given to these disorders has further increased in 7 
the last few years. However, the treatment of said pathologies is quite complex, in part due to challenges in 8 
drug delivery. 9 
The blood-brain barrier (BBB) is the most important physical barrier in brain drug delivery, being estimated 10 
that all macromolecular compounds, and over 98% of low molecular weight drugs, are unable to permeate it, 11 
leading to a very low drug bioavailability at the desired target site. Among the strategies to surpass the 12 
BBB’s low permeability to non-lipophilic drugs, it is possible to consider the bypass offered by the nasal 13 
route, commonly called intranasal (IN) delivery.  14 
The pathways of drug distribution from the nasal mucosa to the brain have been repeatedly and extensively 15 
reviewed over the years (for recent reviews see for example [3–5]). Put simply, the nasal cavity can be 16 
divided in the respiratory and the olfactory regions. In the respiratory region, drugs can either enter the 17 
systemic circulation or be directly transported to the brain tissues through the trigeminal nerve pathway. In 18 
the olfactory region, drugs can be transported or diffuse directly to the brain through the olfactory mucosa 19 
pathway, considered the most important direct pathway [3,5]. Of course, only part of the drug will likely 20 
reach the brain, since a fraction might be locally lost due to mucociliary clearance or enzymatic degradation. 21 
Moreover, part will be absorbed to the systemic circulation, distributed to non-target tissues and finally 22 
eliminated. Nonetheless, with lipophilic drugs, a fraction of what reaches the systemic circulation will still 23 




Fig. 1. Schematic representation of intranasal (IN) delivery’s direct and indirect pathways. After instillation, the drug can 2 
either: a) suffer mucociliary clearance (MCC); b) reach the respiratory region, where it will either enter the systemic 3 
circulation or be directly transported to the brain through the trigeminal nerve pathway (direct pathway); or c) reach the 4 
olfactory region, where it will be transported to the brain through the olfactory mucosa pathway (direct pathway). The 5 
drugs that reach systemic circulation can be distributed to non-target tissues, followed by elimination, or still reach the 6 
brain through the blood-brain-barrier (BBB) (indirect pathway). 7 
 8 
IN delivery can, however, offer advantages even in the delivery of BBB-penetrating drugs. Researchers 9 
working on IN delivery frequently cite the disadvantages of classic administration routes, such as those 10 
related with the invasiveness of parenteral routes (involving injections); the variable bioavailability, slower 11 
onset of action, and low patient compliance of the rectal route; or the unsuitability of the transdermal route in 12 
cases of emergency (passive delivery systems) [6–8]. In what concerns the oral and oromucosal routes, the 13 
limitations are related with altered physiological states of individuals (such as nausea and vomiting, or the 14 
hypersalivation and inability to swallow that happen during an epileptic seizure) [3,4,9–11],  large inter-15 
subject absorption rate variability, slow onset of action, drug-drug and drug-food interactions and 16 
cytochrome P450 induction [8,10,12–17]. Moreover, IN delivery offers the possibility of avoiding hepatic 17 
first pass metabolism and can reduce drug distribution to non-targeted sites, thereby minimizing systemic 18 
adverse effects [8,18–24]. 19 
Even though the nasal route usage in human medicine has been mostly limited to locally acting agents, in 20 
recent years a few systemically acting nasal drug products have been commercialized for menopausal 21 
symptoms, pain control, endometriosis and migraine headache. In addition, researchers exploring the IN 22 
delivery route have also focused on pharmaceuticals intended to treat neurodegenerative and psychiatric 23 
diseases [3].  24 
 
7 
Current marketed nasal preparations are mainly in the form of solutions or suspensions, but labile, low 1 
soluble, low permeant and/or less potent drugs might need a formulation that promotes drug bioavailability 2 
and, preferably, brain targeted delivery. For that purpose nanotechnology may provide some assistance. As 3 
the name suggests, all drug-carrier nanosystems are characterized by a very small size (although the upper 4 
limit is controversial, it is never over 1 µm), which can be suited to transport drugs to target tissues and cells, 5 
where they will ideally release their cargo. The authors give several reasons for their choice of this 6 
formulation strategy: protection of drugs from metabolism and/or chemical degradation; reduction of the 7 
issue of high plasma protein binding (in cases where the nanosystem itself might be absorbed); increased 8 
drug solubility and diffusion through biological membranes; increased half-life and reduction of P-9 
glycoprotein efflux in the BBB [12,13,21,25–28]. These effects, by their turn, can result in enhanced brain 10 
targeting and/or bioavailability, and minimization of overall toxicity due to dose reduction, and increase the 11 
patient’s compliance [4,25,26,29]. However, IN nanosystems could improve the drug’s concentration in non-12 
targeted areas of the brain, leading to possible neurotoxicity. Furthermore, the carrier systems themselves 13 
might originate safety concerns. Pulmonary complications have been reported for aerosol particles sized < 5 14 
µm, due to aspiration to the lungs [4–6,30]. Consequently, each  delivery system must be considered 15 
individually, and with caution.  16 
IN delivery has other general requirements: the pH of the preparation should be similar to the human nasal 17 
mucosa’s (5.0 to 6.5), in order to avoid irritation;  tonicity should be high enough to promote absorption, but 18 
not so elevated that it causes toxicity to the nasal epithelium or enhances mucociliary clearance; careful 19 
consideration should be given to the preparation’s viscosity, as a more viscous preparation enhances contact 20 
time with the nasal mucosa, which can increase permeation, but on the other hand might also reduce 21 
absorption because of decreased drug diffusion. Furthermore, it also has limitations: only a low volume can 22 
be administered (with the human nasal cavity usually retaining up to 200 μL), and therefore needing a 23 
relatively potent drug; it requires biocompatible excipients; and must not have aggressive associated odors 24 
[3,4,6]. All these aspects must be taken into consideration when formulating for IN administration. 25 
Many variables can, therefore, influence the outcomes of in vivo studies comprising IN nanosystem 26 
administration. In the present systematic review, our aim was to analyze the reports of non-clinical brain 27 
targeting studies evaluating IN delivery of small molecule drugs within nanosystems. Our present analysis 28 
focused on study design, chosen nanosystem class and their characterization, and reported output 29 
pharmacokinetic (PK) parameters, with emphasis on searching for associations between brain delivery 30 
efficacy and nanosystem type. 31 
 32 
2. Methods 33 
2.1. Systematic bibliographic selection and data collection 34 
Articles considered for data collection, and consequent statistical analysis, were obtained via search in the 35 
“Web of ScienceTM” database, using the following terms: (nanoemulsion$ OR microemulsion$ OR 36 
submicron OR emulsion$ OR nanostructured OR miniemulsion$ OR nanoparticle$ OR nanosystem$ OR 37 
 
8 
liposome$ OR cubosome$ OR transfersome$ OR niosome$ OR polymersome$ OR exosome$ OR 1 
dendrimer$ OR nanocarrier$ OR micelles) AND brain AND ("in vivo" OR animal OR biodistribution OR 2 
pharmacokinetics OR pre-clinical OR non-clinical) AND (nasal OR intranasal). Date of last search was June 3 
23th 2017 and no publication date restriction was applied. Screening for exclusion criteria was done by title, 4 
abstract and article content, if needed and in that respective order. Those criteria included: being a review 5 
article; not comprising an in vivo pharmacokinetic study; absent or insufficient presentation of the necessary 6 
pharmacokinetic data, more precisely brain and blood AUC values for IN nanosystem and IV formulation; 7 
inexistence of an IV comparison route; drug not having a low molecular weight (namely protein or gene 8 
derived entities); IN drug not being formulated in a nanosystem; being a vector study only, with no 9 
associated drug; being a toxicity study only; lack of information and interpretation quality (repeated errors); 10 
and lastly, impact factor inferior to 1. Data was extracted to a spreadsheet table format by one author and 11 
then thoroughly reviewed by a second author.  12 
2.2. DTE%, DTP%, B%brain IN/IV  and RB%brain (re)calculation 13 
Given the lack of uniformity or absence of the calculation of drug targeting efficiency (DTE%), direct 14 
transport percentage (DTP%), comparative brain bioavailability (IN vs. IV) (B%brain IN/IV) and relative brain 15 
bioavailability (RB%brain) ratios, whenever possible, these were recalculated from reported AUC data. 16 




× 100  (1) 18 
where AUC is the “area under the curve”, representing drug concentration variation over time (in brain or 19 
blood), for the duration of the study (AUC0-t), and IN and IV indicate the administration route to which the 20 
AUC values correspond to [4,7]. As the given formula implies, the DTE% value can be interpreted as the  21 
relative propensity of the drug to accumulate in the brain when administered through the IN route, over the 22 
IV route. Values can range from 0 to +∞. Values above 100% indicate a more efficient brain targeting 23 
through IN administration when compared to IV administration, and values below 100% represent the 24 
opposite  [7].  The log10(𝐷𝑇𝐸%) was also calculated (in attempt to normalize the distributions) and 25 
expressed as Log DTE%. 26 
Even if useful, DTE% might not offer an easy interpretation of which drug fraction was transported through 27 
the olfactory and trigeminal nerve pathways and which was not  [4]. As an alternative, the DTP% can be 28 




× 100  (2) 30 




× 𝐴𝑈𝐶𝑏𝑙𝑜𝑜𝑑 𝐼𝑁 (3). 32 
 
9 
Since the expected contribution of the indirect pathway to AUCbrain IN is subtracted from its total value, 1 
DTP% is, as the name suggests, the value that better represents the drug fraction suffering direct transport to 2 
the brain  [4,7]. Values can theoretically range from -∞ to 100, although the expected value if there is no 3 
transport through the direct nose-to-brain pathways is 0. Values higher than 0 indicate the presence of brain 4 
targeting through the direct pathways, opposite to values from -∞ to 0, which indicate a more efficient brain 5 
targeting through the IV route [7]. A value of 100 is only possible if the drug does not cross the BBB at all 6 
(AUCbrain IV = 0), or if it is not absorbed to the systemic circulation when administered intranasally (AUCblood 7 
IN = 0). An approximation of the first case is more likely to occur, and it means that drugs that are poorly 8 
permeable in the BBB are more likely to have the highest DTP% values. However, DTE% and DTP% can be 9 
high despite very low bioavailability in the brain.   10 
Comparative brain bioavailability (IN vs IV) is a measure of brain drug accumulation through the IN route 11 




× 100  (4) 13 
Values above 100 indicate a better brain drug accumulation through IN administration when compared to the 14 
IV administration. The log10( 𝐵%𝑏𝑟𝑎𝑖𝑛 𝐼𝑁/𝐼𝑉) was used and expressed as Log B%brain IN/IV. 15 
Relative brain bioavailability (RB%brain) is similar to B%brain IN/IV, only IN nanosystem delivery is here 16 




× 100  (5) 18 
Values above 100 will indicate a better brain drug accumulation through IN administration of the nanosystem 19 
when compared to the IN solution. The log10( 𝑅𝐵%𝑏𝑟𝑎𝑖𝑛) was used and expressed as Log RB%brain. 20 
The comparison of the efficiency in brain targeting between IN nanosystems relatively to IN solutions was 21 
also verified by calculating, in analogy with Log RB%, the logarithm of relative DTE%, (Log RDTE%) and 22 
of relative DTP% (Log RDTP%). The following formulas where applied: 23 
𝐿𝑜𝑔 𝑅𝐷𝑇𝐸% = log10 (
𝐷𝑇𝐸%𝐼𝑁𝑛𝑎𝑛𝑜𝑠𝑦𝑠𝑡𝑒𝑚
𝐷𝑇𝐸%𝐼𝑁𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
× 100)    (6) 24 
𝐿𝑜𝑔 𝑅𝐷𝑇𝑃% = log10 (
𝐷𝑇𝑃%𝐼𝑁𝑛𝑎𝑛𝑜𝑠𝑦𝑠𝑡𝑒𝑚
𝐷𝑇𝑃%𝐼𝑁𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
× 100) (7) 25 
2.3. Statistical analysis 26 
Statistical analysis was performed using Prism software, version 6.0, from GraphPad. Normality of variables 27 
distribution was assessed with the D’Agostino-Pearson omnibus normality test. For normal distributions, 28 
group mean values were compared with a reference value using the one sample t-test (also in the case of 29 
insufficient representation, with n < 6). In the case of non-normal distributions (and sufficient 30 
representation), median values and a Wilcoxon signed-rank test were used. Differences between mean 31 
 
10 
attribute values of nanosystem groups that were at least minimally represented (n ≥ 5) were evaluated by one-1 
way analysis of variance (ANOVA) with the Tukey multiple comparisons post-test, as were the general mean 2 
differences between IN solutions, IN nanosystems and IV formulations (when analyzed as a whole). The 3 
overall median differences between IN solutions and nanosystems were evaluated by the Mann-Whitney 4 
location test. Conservative outlier analysis was performed using the ROUT method (combined Robust 5 
regression and Outlier removal) setting Q at 0.1%. 6 
 7 
3. Results and discussion 8 
3.1. Bibliographic search results characterization and quality of reported variables 9 
Of the obtained 243 search results, only 56 met the inclusion/exclusion criteria. Interestingly, the countries of 10 
origin were India (66%), Egypt (18%), China (12%), and Saudi Arabia (4%). All articles selected for analysis 11 
were published between 2004 and mid-2017, most of them (34%) being published in the year of 2016, and 12 
more than half in the last 3 years (2014-2016) (Fig. 2). Therefore, there seems to be an increasing interest in 13 
intranasal delivery of nanosystems and their in vivo brain targeting evaluation. Journal impact factors varied 14 
from 1.566 to 5.434 (median value of 3.773).  15 
 16 
 17 
Fig. 2. Increase in the number of publications on the topic of the present review over time. Data correspond to cumulative 18 
publication frequency per year of publication.  19 
Essential parameters such as animal model, study duration, IV formulation and IN nanosystem type, drug and 20 
analytical method were described in every single article. On the other hand, the analytical method validation 21 
was only mentioned in 30% of all publications, while one should expect to find the validation parameters 22 
described. Most articles indicated DTE%, Tmaxbrain IN, Tmaxblood IN and Tmaxbrain IV. Tmaxblood IV was only 23 
mentioned in 75% of publications because some consider it to be equal to zero, as the drug is readily 24 
available in the bloodstream (a possible reason for other values might be considering Tmaxblood IV to be the 25 
minimum time at which the blood samples were collected). DTP% follows DTE% as the second most 26 
reported pharmacokinetic ratio. B%brain IN/IV had a low report rate, and RB%brain even lower (close to none). 27 
Instead, comparative brain AUC fold-changes were sometimes calculated, but they are basically the same 28 
(ratio instead of a percentage value).  29 
 
11 
DTE% and DTP%, being ratios that utilize the exact same data, were expected to have a perfect monotonic 1 
(non-linear) correlation between them. By examining the scatter-dot plot representations of the correlation 2 
between both ratios as mentioned in the articles (Fig. 3A), it can easily be seen that there was an 3 
inconsistency in some of the values calculated by the authors, with some very strong outliers standing out. 4 
Meanwhile, DTE% and DTP% values recalculated by us, using the above-mentioned formulas, had a perfect 5 
monotonic correlation (Spearman’s correlation coefficient of 1, Fig. 3B). 6 
 7 
Fig. 3. Correlation of DTE% and DTP% ratios. Representation of DTE% vs DTP% values as given in the articles (rS = 8 
0.646) (A) and of DTE% and DTP% as recalculated (rS = 1.000) (B). DTE - drug targeting efficiency; DTP – direct 9 
transport percentage; rs - Spearman’s correlation coefficient. 10 
 11 
Of all pharmacokinetic ratios, DTE% was the most mentioned, however only 49% of all articles exhibited a 12 
value that could be considered equivalent to our recalculated ones. Some reasons for the discrepancies in 13 
DTE% were: the use of either AUC∞ or a different AUC0-t value for the calculation, while we used AUC0-t 14 
values corresponding to the duration of the experiment (considering time from zero to the last measurable 15 
concentration); the use of AUC0-t for calculation, but then only presenting AUC∞ values, which we used since 16 
we didn’t have access to additional data; calculation of DTE using the AUC0-t of the nanosystems 17 
administered IV, while we recalculated them using AUC0-t of the IV solutions when reported; and the use of a 18 
different formula (or non-disclosure of the formula) for the calculation [13,32–37]. For many other cases, we 19 
could find no further clear justification for the revealed discrepancies. 20 
For DTP% and B%brain IN/IV, 63% and 35% of the articles reporting these values, respectively, displayed 21 
calculated values similar to ours. Furthermore, it is relevant to mention that B%brain IN/IV values were either 22 
phrased as “absolute brain bioavailabity”, “nasal bioavailability” or “comparative bioavailability”, and also 23 
that it was sometimes hard to determine whether the authors were referring to brain or blood bioavailability, 24 
which made it confusing to interpret. Relative bioavailability values were only provided in 2 articles, both 25 
with natural discrepancies in comparison with the ones we calculated, since we used reported AUC0-t and the 26 
authors used AUC∞ [11,31]. All these discrepancies, numeric or not, are evidence of a lack of systematization 27 
between studies. 28 
 
12 
As for formulation attributes, most articles reported nanosystem particle size (determined by dynamic light 1 
scattering) and zeta potential. However, zeta potential is a measure dependent on both particle charge and salt 2 
composition of the medium used for particle dilution, and these were not always described. It is often taken 3 
as a recommendation that its absolute value should be above 30 mV for maximum stability [15,20,21,38]. A 4 
direct electrostatic adsorptive interaction with the mucosa is usually expected with high positive zeta 5 
potential values, which justifies that chitosan, a natural cationic polymer, is one of the most mentioned 6 
mucoadhesive agents [12,25,39]. The polydispersity index (PDI) was also frequently but not always 7 
mentioned, and nanosystems’ size is not completely characterized without it [32]. The PDI is also very 8 
important in drug pharmacokinetics, since a lower value indicates an enhanced  probability of a more 9 
uniform absorption through the nasal mucosa and a higher value may lead to pharmacokinetic irregularity 10 
and variability in the therapeutic outcome [22,40]. It is usually recommended that the PDI is below 0.5 11 
[12,20,33]. On the other hand, pH and viscosity were described fewer times. Little more than half of all 12 
articles reported formulation pH, and in those that did, it ranged from 4.62 to 7.00, which is fairly within the 13 
human nasal mucosa’s physiologic range [3]. In addition to having a low reporting rate, viscosity had 14 
associated different measurement temperatures (mostly 25 ºC, but also 33 ºC), rotation speeds and spindle 15 
types, which makes it hard to interpret. All these formulation attributes can be critical in drug absorption 16 
and/or safety, and should be reported in every article. 17 
Other important parameters such as in vitro release and ex vivo permeation of the drug, although mentioned 18 
in some of the articles, will not be considered for analysis. This is because only about one half and one third 19 
of all publications had, respectively, done these in vitro and ex vivo studies. Furthermore, with the reported 20 
release and permeation  studies’ duration, temperature and rotation speed varied substantially from one 21 
article to another, or were not mentioned at all, and membrane pore (in vitro) and nasal mucosa model (ex 22 
vivo) also varied greatly. 23 
3.3.  Delivered drugs 24 
In a total of 56 articles, 39 different drugs were studied, with only one article studying 2 drugs 25 
simultaneously (herbal compounds borneol and geniposide, components of the same Chinese traditional 26 
medicine) [29]. They belonged most frequently to the antipsychotics, dopaminergic agents, antiepileptics and 27 
anxiolytics classes, but many other were represented (Table 1). This large heterogeneity, although justifiable 28 
by the need to innovate, and therefore to formulate different drugs, makes it difficult to compare, in a direct 29 
manner, values of different nanosystems without a great risk of introducing a substantial bias into data 30 
interpretation. Even in the case of the most studied drug, olanzapine, an atypical antipsychotic used for the 31 
treatment of schizophrenia (which was mentioned in 5 articles) there were 8 different nanosystems: 32 
mucoadhesive and non-mucoadhesive nano and microemulsions, polymeric nanoparticles, transfersomes, 33 
liposomes and nanocubic vesicular systems. These nanosystems, even if all studied in the same animal model 34 
(rat), had associated different analytical methods, IV comparison formulations, study durations, doses and 35 
excipients [31,38,41–43]. 36 
  37 
 
13 
Table 1. Anatomical Therapeutic Chemical Classification (ATCC) of the formulated drugs*, and respective reference. 1 
ATCC Chemical entities (name) Papers (ni) Ref.s 
A04A Antiemetics and antinauseants Ondansetron (hydrochloride) 1 [44] 
C04A Peripheral vasodilators Ergoloid mesylate 1 [45] 
C05C Capillary stabilizing agents Rutin 1 [35] 
C08C Selective calcium channel blockers with 
mainly vascular effects 
Nimodipine 2 [46,47] 
G03F Progestogens and estrogens in combination Estradiol 1 [48] 
J05A Direct acting antivirals Saquinavir (as mesylate) 1 [49] 
L01A Alkylating agents Temozolomide 1 [18] 
M03B Muscle relaxants Cyclobenzaprine (hydrochloride), 
Tizanidine 
2 [39,50] 
N02A Opioids Tramadol 1 [36] 
N02C Antimigraine preparations Sumatriptan, Sumatriptan (as succinate), 
Zolmitriptan 
4 [9,10,51,52] 
N03A Antiepileptics Carbamazepine, Clonazepam, 
Oxcarbazepine 
5 [11,14,17,40,53] 
N04B Dopaminergic agents Bromocriptine, Cabergoline, Rasagiline, 
Ropinirole 
6 [22,54–56] 
N05A Antipsychotics Asenapine (as maleate), Haloperidol, 
Olanzapine, Paliperidone, Risperidone, 




N05B Anxiolytics Alprazolam, Buspirone (as 
hydrochloride), Clobazam, Diazepam 
5 [8,12,28,59] 
N06A Antidepressants Duloxetine, Venlafaxine 3 [15,16,60] 
N06D Anti-dementia drugs Rivastigmine, Tacrine (as 
hydrochloride) 
2 [33,61] 
P01B Antimalarials Artemether (as artemisinin methyl ether) 1 [62] 
Experimental Resveratrol, Tarenflurbil 2 [63,37] 





ni, - absolute frequency; Ref.s – bibliographic references; * all ATCC obtained from the DrugBank Version 5.0.7 database [67] 2 
 3 
3.4. Delivery nanosystems 4 
From the 56 articles that were analyzed, 31 focused on the study of one formulation of only one nanosystem 5 
type, while 25 studied two or more. Reasons for studying more than one formulation included, more 6 
frequently, the addition of a mucoadhesive agent, but also other variations in constituents (different 7 
surfactants, PEGylation, variation of polymers’ molecular weight, addition of cyclodextrins). Fewer times, 8 
there was also the comparison of two nanosystem types, or drugs (two different drugs, or chemical 9 
derivatives of the same drug). 10 
Formulations were here classified using a two level classification system (Table 2). On level I we grouped 11 
them in a minimum number of nanosystem types: emulsions, polymeric nanosystems, lipid nanoparticles , 12 
and liposome related nanosystems. On level II, the detail in nanosystem distinction was increased, using a 13 
classical class definition. Rare nanosystems, containing phospholipids in their composition, occurring one 14 
 
14 
time only, were grouped in the same class, named “other” (niosomes, nanocubic vesicular systems, 1 
emulsomes and lipidic micelles). 2 
Table 2. Frequency distribution of formulations by nanosystem class using a two level classification system. 3 
Level I  - groups ni Level II - classes ni Formulations compared to 
IN solutions* (ni) 
Emulsions 50 Microemulsions 36 26 
Nanoemulsions 14 12 
Polymeric nanosystems 26 Polymeric nanoparticles 21 19 
Polymeric micelles  5 5 
Lipid nanoparticles 8 Solid lipid nanoparticles 3 2 
Nanostructured lipid carriers 5 4 
Liposome related nanosystems 10 Liposomes 4 0 
Transfersomes 2 0 
Other 4 0 
N 94  94 68 
ni - absolute frequency; N - total number of events; IN – intranasal; *  or drug dispersions (one case). 4 
 5 
Regarding the frequency of formulation types in the analyzed data, emulsions were the most studied delivery 6 
nanosystem group, comprising more than half of all formulations (Table 2). Within that group, 7 
microemulsions were the most studied class. 8 
Nanometric emulsions (colloidal liquid in liquid dispersions) include nanoemulsions and microemulsions, 9 
not always clearly distinguished in literature. Theoretically, while the first have thermodynamic stability, the 10 
later do not. Nanoemulsions have, nonetheless, a relatively high kinetic stability [14,27,36], a higher surface 11 
area and higher free energy than macroemulsions, being more stable against sedimentation, flocculation, 12 
coalescence and creaming [37]. Given that water is added to a mixture of oil, surfactant and co-surfactant, 13 
both types of emulsions are said to form spontaneously [3,29]. Droplet size range is generally lower in 14 
microemulsions (10-100 nm) than in nanoemulsions (20-200 nm), but it is questionable whether it is accurate 15 
to simply identify a system as microemulsion when it is translucent. It only means that most droplets are very 16 
small in diameter, and partially translucent systems could either be macroemulsions or nanoemulsions. Their 17 
lipophilic nature, good permeability and solubilizing effect also make them promising systems for IN 18 
delivery, in particular of lipossoluble drugs [20,22,38,49,36]. However, a few reports stated irritation of 19 
gastrointestinal or nasal mucosa with the use of these preparations, justified by the existence of surfactants in 20 
large amounts [45,51]. They also suffer from rapid nasal clearance, but a mucoadhesive agent can be added 21 
to the formulations to overcome mucociliary clearance, leading to a higher residence time at the site of 22 
absorption, and therefore improving bioavailability [12,39].  23 
Polymeric nanosystems followed emulsions in frequency, polymeric nanoparticles (PN) being the most 24 
frequent class in that group (Table 2). PN are compact colloidal systems with a highly variable size range 25 
within the nanometric scale, composed of natural or artificial polymers [3,12]. Drugs will be dissolved, 26 
entrapped, encapsulated or attached to the polymeric matrix [8,12]. Surface hydrophobicity, high drug 27 
loading and controlled release capacity, and the ability to prolong the duration of therapeutic effect, are a few 28 
of their advantages. As in the case of mucoadhesive nano and microemulsions, the integration of 29 
 
15 
mucoadhesive polymers into the PN formulation is expected to lead to a higher residence time on the nasal 1 
mucosa [12,39]. Although there is scientific evidence suggesting the biodegradability and biocompatibility of 2 
the polymers that are generally used, some reports mention toxicity, and also formation of aggregates with a 3 
large size and lack of stability in aqueous dispersion, leading to phase separation [10,28].  4 
Even if made of polymers as well, polymeric micelles (PM) differ in composition from PN: they are 5 
comprised of amphiphilic block copolymers that will self-assembly, forming a hydrophobic core, and a 6 
hydrophilic corona. The core can solubilize and incorporate a lipophilic drug,whyle the hydrophilic corona 7 
will serve as a stabilizing interface between the hydrophobic core and the external aqueous environment. This 8 
kinetic stability and self-assembly in water will only occur above the critical micelle concentration, which is, 9 
however, usually lower than that of small molecule surfactants. Described drawbacks include the formation 10 
of aggregates with a large particle size and lack of stability in aqueous dispersion, resulting in phase 11 
separation [11,31,47]. 12 
Within the lipid nanoparticles group, the best known are perhaps the solid lipid nanoparticles (SLN), which 13 
are solid matricial nanoparticles made of solid lipids dispersed in water or an aqueous surfactant solution 14 
[28]. They are said to have increased drug stability, good biocompatibility and tolerability, and high drug 15 
loading, also increasing nasal retention time due to an occlusive effect and mucous membrane adhesion 16 
[28,57]. Despite many claims of controlled delivery of hydrophobic drugs, some reports have reached 17 
opposite results, which is theoretically explained by authors as drug and lipid solidification in phase-18 
separated crystals that precipitate either in the core or on the surface of the nanoparticles, with a consequent 19 
slow or pronounced burst release [17]. Reports of leakage during storage by lipid polymorphism have also 20 
been mentioned [21,44]. In their turn, instead of only having a solid lipid in their composition, 21 
nanostructured lipid carriers (NLC) have a blend of solid and liquid lipids that form an imperfect crystal 22 
matrix in which drugs can be accommodated in [3,62]. General advantages include rapid uptake, absence of 23 
burst effect and good tolerability. Stated advantages over polymeric nanoparticles comprise avoidance of the 24 
use of organic solvents in production, and over SLN higher drug loading, smaller particle size and no drug 25 
leakage or expulsion during storage, with improved long-term stability [18,21,44,60,62,68].  26 
Within the liposome related nanosystems group, classic liposomes were the most represented class. These are 27 
biocompatible and biodegradable vesicles composed of phospholipid (and cholesterol) bilayers enclosing one 28 
or more aqueous compartments [3,5]. Several variations of these particles have been developed. In 29 
transfersomes the lipidic bilayers specific composition and membrane incorporated edge activators give the 30 
vesicles high flexibility, making it easier for them to interact with the membranes and pass through small 31 
fenestrations [43]. Niosomes are prepared with non-ionic surfactants such as monoester of polyoxyethylene 32 
fatty acids, free fatty acids and cholesterol, and  have a high capacity central core that can deliver a large 33 
volume of active ingredient [10]. Nanocubic vesicular systems have polymeric non-ionic surfactants 34 
integrated in their phospholipidic bilayer, whose very specific ratio in relation to the phospholipid gives the 35 
vesicles cubic shape [42]. Emulsomes have the combined characteristics of emulsions, SLN or NLC and 36 
liposomes: a lipidic core in a solid or liquid crystalline state (instead of an oil fluid phase), surrounded by at 37 
least one phospholipid bilayer envelope, with an aqueous interface in between (hydrophilic heads facing 38 
 
16 
outwards and hydrophobic tails facing inwards). Emulsomes allow high loads of lipophilic drugs and a 1 
prolonged release time. When compared to other lipid carriers, such as SLN and liposomes, these particles 2 
are described as not showing the common preparation methods shortcomings, such as high pressure induced 3 
drug degradation, lipid crystallization, gelation and co-existence of several colloidal species [17]. 4 
Lastly, lipidic polymeric micelles are, just like regular micelles, made of amphiphilic block copolymers, but 5 
those copolymers are now also attached to a phospholipid, which gives origin to a more lipophilic, although 6 
larger, nanosystem [47]. 7 
Furthermore, in the majority of studies (about 72% of all articles) the nanosystems were compared with the 8 
respective drug solutions or, in one case, drug dispersion (Table 2). 9 
3.6. PK study designs and drug assays 10 
Only two animal models were used, rat (75%) and mice (25%). Study duration varied significantly, ranging 11 
between 2 and 72 h, with a median value of 8 h, which was also the duration of almost half of all studies. 12 
Every study used the IV route as a parenteral comparison route, although not all animal subjects were given 13 
an IV drug dispersion, with 39% of all articles administering the nanosystem itself. This is a major 14 
inconsistency, since the PK profile of the intravenously administered drug, in solution or associated to a 15 
nanosystem, can be quite different, and the calculation of DTE%, DTP% and B%brain IN/IV of the IN 16 
formulation should be made using IV drug solution data. For drug assay, the most utilized analytical method 17 
was liquid chromatography (57%), which included high and ultra-performance systems, and was often 18 
coupled with a tandem mass spectrometry detector, followed by scintigraphy (43%). 19 
3.7. Nanosystem attributes  20 
In what concerns mean particle size (Fig. 4A), the most homogeneous formulations between studies, with the 21 
smallest range of values, belonged to the microemulsions class. It also had the lowest mean value, which was 22 
significantly lower than that of the PN. PN had the highest range, having the most heterogeneous particle size 23 
distribution out of the 4 groups, which might be explained by the different subtypes of nanoparticles and their 24 
respective composition and preparation methods. PN also had a significantly higher mean than the PM and 25 
the nanoemulsions classes (aside from the microemulsions). All these results are in agreement with the 26 
theoretical definition of nanosystems size.  27 
Homogeneity of particle size distribution is characterized by PDI values (Fig. 4B), of which microemulsions 28 
had the lowest mean and PN the highest. The difference between means of these two classes was significant, 29 
and the mean of the PN class was also significantly higher than that of the PM and nanoemulsions classes, 30 
which is in accordance with what has been mentioned above. All the PDI values were below the 31 
recommended 0.5 threshold. 32 
As previously mentioned, zeta potential values can be either positive or negative, depending on the combined 33 
charges and quantities of the drugs and excipients that compose the formulation. Positively charged 34 
formulations have, in theory, the advantage of interacting with the negatively charged nasal mucosal 35 
membrane due to the formation of electrostatic bonds with the sialic acid residues that are part of its 36 
 
17 
composition. This facilitates both adhesion and transport by increasing contact time with said region and 1 
amplifying the opening of the tight junctions that exist there [32,35,68]. About half of all nanosystem groups 2 
included negatively charged nanosystems only, and for those that comprised both positively and negatively 3 
charged formulations, most values were also negative (Fig. 4C). Out of the 5 considered classes, 4 
microemulsions had the most negative mean value, and PN the most positive, with the differences between 5 
the two classes being significant. PN also had significant differences when compared to the PM, 6 
nanoemulsions and NLC classes. The more positive values attributed to the PN class might be justified by the 7 
frequent presence of the positively charged polymer chitosan in their composition.  8 
 9 
Fig. 4. Summary of attributes of the drug delivery 10 
nanosystems per class. Particle size (A), PDI (B) 11 
and zeta potential (C) are shown. Data correspond 12 
to median ± inter-quartile interval and range 13 
(box-plot) plus mean indicated by a small “plus” 14 
signal (+). Statistical analysis was done by 15 
applying a one-way ANOVA with the Tukey 16 
multiple comparisons post-test; # p < 0.05; # # p < 17 
0.01; # # # p < 0.001; # # # # p < 0.0001. PDI – 18 
polydispersity index. 19 
 20 
  21 
 
18 
3.9. Drug pharmacokinetics 1 
The median values of Log DTE%, DTP% and Log B%brain IN/IV of all nanosystem formulations grouped 2 
together was superior and significantly different from the median values of the 42 solutions that were also 3 
evaluated (Fig. 5A, B and C). Furthermore, their range of values was extremely high, not only in the 4 
nanosystems group, where one could already expect it, but also in the solution group. This big variability in 5 
drug delivery performance of IN solutions can only be due to either the drug itself or confounding variables 6 
related with study design, such as differences in study duration and administered dose, both of which can 7 
greatly influence the AUC values and, consequently, their ratios. Even a conservative outlier analysis 8 
(ROUT, Q = 0.1%) identified several possible outliers. The very high Log DTE% values in the solution 9 
group (Fig. 5A) corresponded to plant derived drugs [13,35], and are probably due to their high 10 
hydrophilicity and consequent difficulty in permeating the BBB (low brain bioavailability through the IV 11 
route). Some very low DTP% values (negative or close to 0, Fig. 5B) correspond to the nanosystems group, 12 
more specifically to risperidone liposomes, olanzapine liposomes, olanzapine transfersomes and olanzapine 13 
nanocubic vesicular systems (3 independent studies [19,42,43]). Curiously, all these formulations belong to 14 
the LRN group. 15 
 16 
Fig. 5. Comparison of 17 
overall drug delivery by 18 
nanosystems and 19 
solutions. Log DTE% 20 
(A), DTP% (B), Log 21 
B%brain IN/IV (C) of IN 22 
solutions and IN 23 
nanosystems, Tmaxbrain 24 
IN (D) and Log AUC 25 
ratio (brain/blood)IN of 26 
IN solutions, IN 27 
nanosystems and all IV 28 
formulations are shown. 29 
Potential outliers are 30 
signaled by brackets. 31 
Data correspond to 32 
individual values plus 33 
median ± quartiles. 34 
Statistical analysis was 35 
done by applying Mann-36 
Whitney U test when comparing IN nanosystems to IN solutions (control), + + p < 0.01, + + + + p < 0.0001; and by applying 37 
one-way ANOVA with the Tukey multiple comparisons post-test when comparing IN nanosystems, IN solutions and IV 38 
formulations, # p < 0.05; # # p < 0.01; # # # p < 0.001; # # # # p < 0.0001. B%brain IN/IV – comparative brain bioavailability (IN 39 
vs. IV); AUC – area under the curve; DTE% – drug targeting efficiency; DTP% – direct transport percentage; IN – 40 




In the matter of the amount of time it takes the drug to reach maximum concentration in the brain (Tmaxbrain 2 
IN), three possible outliers were identified (Fig. 5D): one IN zolmitriptan nanoemulsion, one IN 3 
thymoquinone PN, and one IV thymoquinone PN, all having Tmax values of 4 h or greater [51,64]. In the 4 
case of the IN zolmitriptan nanoemulsion, the obtained Tmax might be justified by the fact that the authors 5 
quantified the drug in the cerebrospinal fluid, instead of the brain (most articles), a compartment that the drug 6 
may take more time to reach. In the case of the thymoquinone preparations, the high Tmax value could be 7 
due to a slow drug release from the nanosystem, as suggested by the release studies performed for those same 8 
formulations in the considered article. 9 
Log AUC ratio (brain/blood) also had a couple of extremely high values identified as possible outliers (Fig. 10 
5E), both corresponding to the IN geniposide microemulsions [29]. These high values might be justified by 11 
the drugs rapid elimination from the blood, leading to low blood AUC [69,70]. 12 
The parameters DTE%, DTP% and B%brain IN/IV showed an ample value range within each nanosystem class, 13 
with DTE% reaching 4 digits (Fig. 6A, 6C and 6E). This high variability could be due to several factors, such 14 
as nanosystems’ composition (both drug and excipients used) and their properties, in addition to confounding 15 
variables (study design), as discussed. Considering only the most represented nanosystem classes, all 16 
mean/median values of Log DTE%, DTP% and Log B%brain IN/IV were significantly higher than the respective 17 
reference values (0 for DTP%, 2 for Log-transformed ratios). The highest Log DTE% mean/median value 18 
belonged to the PM class, being significantly different from the Log DTE% of microemulsions (one-way 19 
ANOVA). This class also had the second highest Log B%brain IN/IV mean value, which was significantly better 20 
than the microemulsions class, and, even though no statistical significance was found, the highest DTP%. 21 
Microemulsions had some of the lowest mean/median values, having a significantly lower B%brain IN/IV than 22 
PN and NLC, besides PM (one-way ANOVA).  23 
It may strike the eye that liposomes and transfersomes behave poorly, and they were already discussed as 24 
possible outliers. However, all liposomes and transfersomes data came from only two articles, therefore 25 





Fig. 6. Formulations brain targeting and bioavailability summary. Log DTE% (A), Log RDTE% (B), DTP% (C), Log 2 
RDTP% (D), Log B%brain IN/IV (E) and Log RB%brain (F) are represented for the different formulation classes. Data 3 
correspond to median ± inter-quartile interval and range (box-plot) plus mean indicated by a small “plus” signal (+). 4 
Statistical significance of differences between group means evaluated by one-way ANOVA with the Tukey multiple 5 
comparisons post-test, # p < 0.05, # # p < 0.01; # # # p < 0.001; differences between means and reference “no-change” 6 
values by one-sample t-test when normal distribution, Wilcoxon signed-rank test when not (medians), * p < 0.05, ** p < 7 
0.01, *** p < 0.001, **** p < 0.0001. B%brain IN/IV – comparative brain bioavailability (IN vs. IV); DTE% – drug 8 
targeting efficiency; DTP% – direct transport percentage; RB%brain – relative brain bioavailability; RDTE% – relative 9 




Furthermore, the direct comparison of nanosystem behavior to the respective drug solution highlights the 1 
advantage of using nanosystems, eliminating the effect of drugs and confounding variables. To do so, we 2 
compared DTE% and DTP% values of the IN nanosystems and the respective IN solutions (only studies 3 
comparing both were included) by calculating their relative values (RDTE% and RDTP%) plus RB%brain, all 4 
Log-transformed (Fig. 6B, 6D and 6F). In the great majority of cases, the IN nanosystem had better brain 5 
drug targeting and direct transport than the respective solution. Furthermore, microemulsions, nanoemulsions 6 
and PN classes mean/median values were significantly different from zero (Fig. 6B and 6D, one sample t-test 7 
when normal distribution, Wilcoxon signed-rank test when not). Relative bioavailability was also improved 8 
in all groups (Fig. 6F, same statistical analysis). Nevertheless, we shouldn’t consider brain values only, since 9 
high blood values can lead to undesirable systemic side effects. Differences between groups were not 10 
statistically significant (one-way ANOVA). 11 
Taking this analysis into account, among the groups where the analysis had statistical power, microemulsions 12 
were the ones that performed less well (even if still having an improved brain targeting in comparison with 13 
the IV formulation). PM seemed to be the most successful when considering Log DTE% values. However, in 14 
this last class the evaluation of the relative brain targeting (both Log RDTE% and Log RDTP%, Fig. 5B and 15 
5D) failed to show an evident improvement over the respective IN drug solutions. This was due to the fact 16 
that some of the solutions used in these studies performed surprisingly well, and some constituted possible 17 
outliers in the solutions data set, as previously mentioned (Fig. 5A). Therefore, the drug itself seems to 18 
noticeably influence the brain targeting efficiency. In contrast, the increase of relative brain/blood 19 
bioavailability seems less dependent on the drug, and more on the achievement of the nanosystems 20 
themselves. In fact, Log DTE% correlated better (and negatively) with Log(AUCbrain/AUCblood)IV than it 21 
did (positively) with Log(AUCbrain/AUCblood)IN, which indicates that good DTE% (and, consequently, 22 
DTP%) values were mostly due to a low IV brain/blood AUC ratio than due to a high IN brain/blood AUC 23 
ratio (Table 3 and Supplementary material Fig. S1). That could be attributed to the studied drug’s properties, 24 
and its poor BBB permeability. Moreover, the same correlations happen with B%brain IN/IV, but in a lesser 25 
extent, further confirming the influence of IV brain AUC values (that are not included in this ratio’s 26 
calculation). 27 
Table 3. Spearman and Pearson correlations of Log DTE%, Log B%brain IN/IV and logarithm values of relative 28 
bioavailability through the IN route. 29 





rS Spearman p 
value 




rxy Pearson p 
value 
Log DTE% 0.24 0.023 0.29 0.023 -0.76 < 0.0001 -0.73 < 0.0001 0.68 < 0.0001 0.68 < 0.0001 
Log ABbrain% 0.23 0.022 0.13 0.022 -0.44 < 0.0001 -0.47 < 0.0001 - - - - 
B%brain IN/IV – comparative brain bioavailability (IN vs. IV); DTE% – drug targeting efficiency; rS – Spearman’s correlation coefficient; 30 
rxy – Pearson’s correlation coefficient. 31 
 32 
Tmax values’ distribution of each nanosystem class was not able to discriminate significant differences 33 
among nanosystems (ANOVA, supplementary material Fig. S2).  34 
In what concerns relative values, most mean/median values of log transformed relative Tmax in the brain 35 
(Log RTmax brain) of the IN nanosystems compared to the IV route (Fig. 7A), and of the IN nanosystems 36 
 
22 
compared to the respective IN solutions (Fig. 7B), are equal to or below zero, with the small gains only 1 
reaching statistical significance in the most represented class, microemulsions. This indicates that brain 2 
delivery through the IN route can be at least as fast as the IV route, which is in accordance with the 3 
conceived idea that the IN route is a fast route to the brain (when compared with oral administration, for 4 
example). 5 
 6 
Fig. 7. Representation of the Log of IN/IV (A) and nanosystem/solution (B) ratios of Tmax brain values for all 7 
nanosystem groups. Data correspond to median ± inter-quartile interval and range (box-plot) plus mean indicated by a 8 
small “plus” signal (+). Statistical significance of differences between means and reference “no-change” values by one-9 
sample t-test when in presence of normal distribution, Wilcoxon signed-rank test when not (medians), * p < 0.05; IN – 10 
intranasal; IV – intravenous; RTmax – quotient of the time required to reach maximum brain concentration between IN 11 
and IV administration, and IN administration of the nanosystem or the respective solution. 12 
 13 
4. Conclusions and final remarks 14 
Pre-clinical brain targeting studies have generally put in evidence some of the advantages of IN brain drug 15 
delivery and have showed utility in comparing different carrier nanosystems among themselves and with 16 
drug solutions. However, this review showed that there is a high heterogeneity on how these assays have 17 
been conducted, analyzed and reported in scientific literature.  18 
A grater uniformity of future reports of IN brain-targeting studies would help with the interpretation of the 19 
relative value of newly developed formulations. Some recommendations: a plain drug solution should be 20 
used IV instead or in addition to the developed nanosystem whenever possible, since the nanosystem itself 21 
can markedly alter the intrinsic PK and biodistribution of the drug; the validation parameters of analytical 22 
methods should be described; PK ratios calculation (formulas and definition terms) should always be 23 
reported; when comparing different formulations, DTE% and B% should preferably be compared after 24 
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logarithmic transformation; the animal model could be harder to standardize, due to variable resources and 1 
administration techniques, but given the elevated number of animals required to characterize drug AUC in 2 
the brain, the use of mice, and a minimum study duration of 8 h, might be good compromises.  3 
Regarding the characterization of the formulations, in order to promote the progressive understanding of the 4 
factors that influence brain targeting, it should be as complete as possible. Formulations’ characterization 5 
should include the nanosystem itself (mean hydrodynamic size, PDI, and zeta potential, detailing the 6 
conditions of its determination), and the final preparation (osmolality, pH, and viscosity, including 7 
temperature and velocity dependence), given the relevance of all these factors in nasal delivery. Drug release 8 
kinetics and the interaction with cells in the nasal mucosa are other important factors that can be informative, 9 
and further work to promote in vitro tests standardization is still required. 10 
Nevertheless, the existing non-clinical brain targeting studies of IN delivery of small drugs, although likely 11 
naturally biased for success cases, confirmed the expectation regarding the advantage of the IN route and the 12 
use of carrier nanosystems. Almost all (reported) nanosystems had favorable targeting ratios, and these were 13 
higher than the comparative IN drug solution. Moreover, success has been obtained for a large group of drugs 14 
already. 15 
Regarding nanosystem classes, microemulsions (the most represented class, with the lowest mean particle 16 
size and lowest value range) and PN (the second most represented, with the highest mean particle size and 17 
highest value range) were only significantly different regarding Log B%brain IN/IV, which was higher for PN, as 18 
it was for PM and NLC (also in comparison with microemulsions). These differences were lost when 19 
considering the comparison of nanosystems with the respective IN drug solution, especially in the case of 20 
PM, where the number of reports is still small. This happened because some drugs reached the brain so 21 
efficiently, even as drug solutions, that further benefit from nanosystems became less evident.  That being 22 
said, it was not possible, from the current global analysis, to clearly discriminate the overall superiority of a 23 
nanosystem class in relation to another with respect to brain targeting and bioavailability. We are only able to 24 
conclude that, in the reported works, nanosystems do seem to be better than the respective drug solutions, 25 
particularity regarding brain bioavailability.  26 
It is important to mention that, given the restrictive nature of the applied inclusion/exclusion criteria, it is not 27 
possible to generalize our results. In fact, only low molecular weight entities were included (protein and gene 28 
derived drugs were left out). Moreover, some nanosystem classes are underrepresented or have not been 29 
represented at all, because many studies describing IN nanosystem development do not design in vivo studies 30 
for DTE% or DTP% calculation. 31 
Other factors, such as drug and nanosystem properties, are variables that might strongly influence the relative 32 
efficacy of a nanosystem. Furthermore, bias could derive from substantial differences in study design. Study 33 
duration, IV formulation, animal model, analytical method and drug dosage are all factors that could 34 
influence the results in a great extent. In any case, we, as others have before us [6], would like to recognize 35 
that the extrapolation of results from animal models to humans carries a risk, since anatomy and physiology 36 
and, consequently, nanosystem performance is likely to be substantially different. Furthermore, performance 37 
 
24 
in both animals and humans might also be influenced by the delivery device itself, a variable that is mostly 1 
overlooked [3].  2 
Future work will explore the presented data further, trying to identify factors in study design, formulation 3 
composition and properties that associate with pharmacokinetic results, and how they interact or exert their 4 
influence, in order to guide the design of future experiments and formulations. 5 
 6 
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Fig. S1. Graphical representation of the correlation of Log DTE% with Log B%brain IN/IV and Log AUC ratios. 3 
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 5 
Fig. S2. Representation of Tmaxbrain IN values for all nanosystem groups. Data correspond to median ± inter-quartile 6 
interval and range (box-plot) and mean indicated by a small “plus” signal (+). IN – intranasal; Tmax – time required to 7 
reach maximum concentration. 8 
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